Ye Wen, He Liping, Su Lei, Zheng Zhousan, Ding Meilin, Ye Sheng
Department of Oncology, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, China.
Department of Geriatrics, Sun Yat-Sen University First Affiliated Hospital, Guangzhou, China.
Front Oncol. 2022 Apr 4;12:868654. doi: 10.3389/fonc.2022.868654. eCollection 2022.
Gastric cancer is one of the most common malignant tumors and patients show a short survival, those combined with bone marrow invasion have a median survival of only 37 days. Here we reported the treatment of a 47-year-old male with advanced gastric cancer and complicated with bone marrow invasion and extensive metastases, who did not tolerate chemotherapy, under monotherapy with savolitinib, a MET receptor tyrosine kinase inhibitor. Before treatment, the patient was in severe pain and presented with thrombocytopenia and hemorrhagic anemia. Savolitinib was given based on amplification and rearrangement of the gene in his tumor. After savolitinib treatment, the patient's condition promptly improved, efficacy evaluation indicated partial remission, and the patient was alive and remained progression-free at 15 weeks at the time of reporting. No obvious adverse reactions occurred. Besides, another case of a female gastric cancer patient with amplification who received savolitinib monotherapy as a third-line treatment that remained progression-free at 12 weeks was also reported. This report provides a new reference for understanding abnormalities in gastric cancer and offers a possibility for future application of MET tyrosine kinase inhibitors in the therapy of gastric cancer with abnormalities. Also, it suggests that sequencing of can be considered a routine target in advanced gastric cancer patients.
胃癌是最常见的恶性肿瘤之一，患者生存期较短，合并骨髓侵犯的患者中位生存期仅37天。在此，我们报告了一名47岁晚期胃癌男性患者的治疗情况，该患者合并骨髓侵犯和广泛转移，不耐受化疗，接受了MET受体酪氨酸激酶抑制剂赛沃替尼单药治疗。治疗前，患者疼痛剧烈，伴有血小板减少和出血性贫血。赛沃替尼根据其肿瘤中该基因的扩增和重排情况给药。赛沃替尼治疗后，患者病情迅速改善，疗效评估显示部分缓解，报告时患者存活，15周时无疾病进展。未发生明显不良反应。此外，还报告了另一例女性胃癌患者，该患者该基因扩增，接受赛沃替尼单药作为三线治疗，12周时无疾病进展。本报告为理解胃癌中的该异常情况提供了新的参考，并为未来MET酪氨酸激酶抑制剂在治疗存在该异常的胃癌中的应用提供了可能性。此外，它还表明该基因测序可被视为晚期胃癌患者的常规靶点。
